Lifecore Biomedical, Inc. announced consolidated financial results for the fourth quarter and seven-month transition period ended December 31, 2025, reporting Q4 revenues of $35.7 million and transition period revenues of $75.5 million, alongside organizational initiatives improving margins. The company provided 2026 guidance of $120-$125 million in revenue and made available investor presentation materials.
Key takeaways
Transition period revenues of $75.5 million, 20% above prior comparable period ended December 31, 2024
Transition period net loss of $18.0 million, improved from $30.6 million in prior comparable period
Transition period Adjusted EBITDA of $13.1 million, $10.5 million above prior comparable period
Q4 2025 revenues of $35.7 million, 10% increase versus quarter ended November 24, 2024
2026 guidance: total revenue $120-$125 million, net loss $32.9-$28.9 million, Adjusted EBITDA $20.5-$25 million
Signed five new programs during transition period, including two commercial site transfers
Ended December 31, 2025 with $38.9 million liquidity, including $17.5 million cash